Please use this identifier to cite or link to this item:
https://scholarbank.nus.edu.sg/handle/10635/129755
DC Field | Value | |
---|---|---|
dc.title | Beneficial effects of high-dose losartan in IgA nephritis | |
dc.contributor.author | Woo, K.-T. | |
dc.contributor.author | Chan, C.-M. | |
dc.contributor.author | Tan, H.-K. | |
dc.contributor.author | Choong, H.-L. | |
dc.contributor.author | Foo, M. | |
dc.contributor.author | Vathsala, A. | |
dc.contributor.author | Lee, E.J.C. | |
dc.contributor.author | Tan, C.-C. | |
dc.contributor.author | Lee, G.S.L. | |
dc.contributor.author | Tan, S.H. | |
dc.contributor.author | Lim, C.-H. | |
dc.contributor.author | Chiang, G.S.C. | |
dc.contributor.author | Fook-Chong, S. | |
dc.contributor.author | Wong, S.K.S. | |
dc.date.accessioned | 2016-11-08T09:58:12Z | |
dc.date.available | 2016-11-08T09:58:12Z | |
dc.date.issued | 2009-06 | |
dc.identifier.citation | Woo, K.-T., Chan, C.-M., Tan, H.-K., Choong, H.-L., Foo, M., Vathsala, A., Lee, E.J.C., Tan, C.-C., Lee, G.S.L., Tan, S.H., Lim, C.-H., Chiang, G.S.C., Fook-Chong, S., Wong, S.K.S. (2009-06). Beneficial effects of high-dose losartan in IgA nephritis. Clinical Nephrology 71 (6) : 617-624. ScholarBank@NUS Repository. | |
dc.identifier.issn | 03010430 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/129755 | |
dc.description.abstract | Aim: Several short-term studies have reported the efficacy of high-dose ARB in reducing proteinuria in patients with diabetic nephropathy. The benefits of long-term high-dose ARB losartan in IgA nephritis have not been explored. Method: This was a 6-year randomized trial in 207 patients with IgA nephritis comparing high-dose ARB (losartan 200 mg/day) with normal dose ARB (losartan 100 mg/day), normal dose ACEI (20 mg/day) and low-dose ACEI (10 mg/day). Multivariate ANOVA was used to test the effect of drug treatment on both eGFR and total urinary protein (TUP). Results: Comparing patients on high-dose ARB (n = 63) with those on normal dose ARB (n = 43), normal dose ACEI (n = 61) and low-dose ACEI (n = 40), patients on high Dose ARB had significantly higher eGFR (p < 0.0005) and lower proteinuria (p < 0.005) at the end of the study. The loss in eGFR was 0.7 ml/min/year for high-dose ARB compared to 3.2 - 3.5 ml/min/year for the other 3 groups (p = 0.0005). There were more patients on high-dose ARB with improvement in eGFR compared to other 3 groups (p < 0.001). Conclusion: Data from this study suggest that high-dose ARB therapy is more efficacious in reducing proteinuria and preserving renal function when compared with normal dose ARB and ACEI. In Year 5, patients on high-dose ARB had a gain in eGFR suggesting that there is possibility of recovery of renal function in these patients on long-term high-dose therapy. © 2009 Dustri-Verlag Dr. K. Feistle. | |
dc.source | Scopus | |
dc.subject | ACEI | |
dc.subject | ARB | |
dc.subject | Glomerular filtration rate | |
dc.subject | Proteinuria | |
dc.subject | Renal failure | |
dc.subject | Treatment | |
dc.type | Article | |
dc.contributor.department | MEDICINE | |
dc.description.sourcetitle | Clinical Nephrology | |
dc.description.volume | 71 | |
dc.description.issue | 6 | |
dc.description.page | 617-624 | |
dc.description.coden | CLNHB | |
dc.identifier.isiut | NOT_IN_WOS | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.